Ibrutinib/Venetoclax Combo Demonstrates Sustained TEAE-Free PFS in First-Line CLL
Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.
Related Articles
Dr Brentjens on Efforts to Expand CAR T-Cell Therapy Beyond B-Cell Malignancies
Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell therapy and ongoing efforts to expand its application beyond B-cell malignancies.
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Nivolumab plus ipilimumab–based treatment regimens have shown long-term, durable efficacy benefits in patients with metastatic NSCLC. Here we report clinical outcomes from a pooled analysis…
A Nuanced Understanding of Cellular Biology Advances Neuro-Oncology Practice: With D. Ross Camidge, MD, PhD; and Adrienne A. Boire, MD, PhD
Drs Camidge and Boire discuss Dr Boire’s path to becoming a physician-scientist and how cellular biology research can improve outcomes for patients with cancer.
An Assortment of Journal Abstracts to Enhance Oncology Care : Oncology Times
An abstract is unavailable.
Welcome! You are invited to join a webinar: AHNS Virtual Education Series: Recon ‘Round the World: Africa – “Mandibular and Maxillary Reconstruction”. After registering, you will receive a confirmation email about joining the webinar.
Presented by the AHNS Reconstructive Head & Neck Surgery Section Moderator: Chad Zender, MD, Professor Otolaryngology, Director Head and Neck Surgery, University Of Cincinnati AHNS…
Oncology Experts Preview Top Abstracts to be Shared at 2025 ASCO GI
Tanios S. Bekaii-Saab, MD, and Yelena Y. Janjigian, MD, preview top presentations from this year’s Gastrointestinal Cancers Symposium.
Patient-Matched Tumor-Normal Sequencing
During our combined 35 years working to advance diagnostic capabilities for cancer—as a pathologist and as a bioinformatician, respectively—we’ve had the opportunity to help build…
OST-HER2 Extends 12-Month EFS in Osteosarcoma With Lung Metastases
OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years in recurrent, fully resected osteosarcoma and lung…
Youtube Icon
Optimizing Treatment Strategies for Localized and Advanced Genitourinary MalignanciesPresented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education.
Fox Chase Cancer Center Scientist Yash Chhabra Honored With NextGen Stars Award From American Association for Cancer Research
PHILADELPHIA (January 21, 2025) — Yash Chhabra, PhD, Assistant Professor in the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, was recently…